TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22956840

Group type: EXPERIMENTAL
Intervention: Kinship-related social scenarios evocative of affiliative emotion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional MRI
Number of subjects: 0
Study: 19740732

Group type: EXPERIMENTAL
Intervention: Accelerated Skill Acquisition Program (ASAP) rehabilitation for 3 weeks
Number of subjects: 5
Study: 17969467

Group type: EXPERIMENTAL
Intervention: Low-dose alcohol (0.03% BAC) after extended wakefulness (18-21 hours awake)
Number of subjects: 19

Group type: COMPARATOR
Intervention: No alcohol after extended wakefulness (18-21 hours awake)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Low-dose alcohol (0.03% BAC) in a non-sleep-deprived state
Number of subjects: 19

Group type: COMPARATOR
Intervention: High-dose alcohol (0.05% BAC) in a rested state
Number of subjects: 19
Study: 15155300

Group type: EXPERIMENTAL
Intervention: Intrathecal midazolam 2 mg, fentanyl 10 micro g
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fentanyl 10 micro g
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intrathecal midazolam alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of intrathecal midazolam and fentanyl
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intrathecal midazolam and fentanyl
Number of subjects: 30
Study: 11446941

Group type: EXPERIMENTAL
Intervention: BIS monitoring (group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard monitoring (group A)
Number of subjects: 40
Study: 9174307

Group type: EXPERIMENTAL
Intervention: Patient-controlled propofol sedation (PCS) combined with a basal infusion of propofol (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Neurolept analgesia using an initial bolus dose of fentanyl (0.7 microg/kg) and droperidol (0.04 mg/kg) followed by a fentanyl infusion (n = 15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patient-controlled propofol sedation (PCS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Neurolept analgesia
Number of subjects: 30
Study: 1532586

Group type: EXPERIMENTAL
Intervention: Estrogen treatment (oral ethinylestradiol, 150 micrograms daily + intramuscular polyestradiol phosphate, 80 mg/mo)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 31
Study: 3084975

Group type: EXPERIMENTAL
Intervention: Psychiatric consultation and management suggestions to primary physicians
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no psychiatric consultation initially)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Psychiatric consultation after crossover from control
Number of subjects: 38
Study: 30395180

Group type: EXPERIMENTAL
Intervention: 3-step hand hygiene technique
Number of subjects: 2923

Group type: COMPARATOR
Intervention: 6-step hand hygiene technique
Number of subjects: 2923
Study: 29331663

Group type: EXPERIMENTAL
Intervention: Mitomycin (40 mg)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Oxaliplatin (200 mg/M2)
Number of subjects: 121
Study: 26769788

Group type: EXPERIMENTAL
Intervention: e‐assessed postoperative recovery follow‐up daily for 14 days via smartphone app including the Swedish web‐version of Quality of Recovery (SwQoR)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: standard care (no follow-up)
Number of subjects: 1000
Study: 24730757

Group type: EXPERIMENTAL
Intervention: Backward treadmill walking
Number of subjects: 88

Group type: COMPARATOR
Intervention: Forward treadmill walking
Number of subjects: 88
Study: 22257543

Group type: EXPERIMENTAL
Intervention: EC‐MPS 1,440 mg/d with reduced tacrolimus (n = 46)
Number of subjects: 94

Group type: COMPARATOR
Intervention: EC‐MPS 720 mg/d with unchanged tacrolimus (n = 48)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: EC‐MPS 1,440 mg/d
Number of subjects: 94

Group type: COMPARATOR
Intervention: EC‐MPS 720 mg/d
Number of subjects: 94
Study: 20682157

Group type: EXPERIMENTAL
Intervention: Lung hyperinflation maneuver (LHM) using bilevel positive pressure (BIPAP) with expiratory pressure of 20 cmH(2)O and inspiratory pressure of 20 cmH(2)O for 1 to 2 minutes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LHM and Control Group
Number of subjects: 20
Study: 17391791

Group type: EXPERIMENTAL
Intervention: Escalated CFRT (74Gy/37f) with neo-adjuvant androgen suppression
Number of subjects: 862

Group type: COMPARATOR
Intervention: Standard CFRT (64Gy/32f) with neo-adjuvant androgen suppression
Number of subjects: 862

Group type: EXPERIMENTAL
Intervention: Both groups (Escalated and Standard CFRT)
Number of subjects: 862
Study: 15811735

Group type: EXPERIMENTAL
Intervention: Oral acetazolamide 500 mg 1 hour preoperatively followed by 250 mg every 6 hours
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Topical brinzolamide 1% 1 drop every 12 hours starting immediately after speculum removal
Number of subjects: 52

Group type: COMPARATOR
Intervention: No ocular hypotensive medication (Control group)
Number of subjects: 52
Study: 11966940

Group type: EXPERIMENTAL
Intervention: New formulation CLOtest
Number of subjects: 335

Group type: COMPARATOR
Intervention: Standard CLOtest
Number of subjects: 335
Study: 9790625

Group type: EXPERIMENTAL
Intervention: Releasable sutures
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional interrupted sutures
Number of subjects: 30
Study: 7620694

Group type: EXPERIMENTAL
Intervention: Vagimid 500 tablets (500 mg metronidazole)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vagimid vaginal tablets (100 mg metronidazole)
Number of subjects: 16
Study: 2148221

Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Outpatient treatment
Number of subjects: 476

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 476
Study: 7399805

Group type: EXPERIMENTAL
Intervention: Husband participation in all treatment sessions
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Husband participation in the first four sessions
Number of subjects: 37

Group type: COMPARATOR
Intervention: No husband involvement
Number of subjects: 37
Study: 31380563

Group type: EXPERIMENTAL
Intervention: Bovine xenograft
Number of subjects: 44

Group type: COMPARATOR
Intervention: Porcine xenograft
Number of subjects: 44
Study: 31084572

Group type: EXPERIMENTAL
Intervention: Audiovisual interviews
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Audio-only interviews
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isolated sentences
Number of subjects: 60

Group type: COMPARATOR
Intervention: Undegraded isolated sentences (control)
Number of subjects: 60
Study: 28989278

Group type: EXPERIMENTAL
Intervention: WB‐EMS and protein supplementation (WB‐EMS&P)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Isolated protein supplementation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nonintervention control
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: WB‐EMS
Number of subjects: 100
Study: 26476467

Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloon (DCB)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty (PTA)
Number of subjects: 331
Study: 23322527

Group type: EXPERIMENTAL
Intervention: Test formulation (Risperidone tablet; Dr. Reddy's Laboratories Ltd.)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation (Risperdal(®) tablet; Xian‐Janssen Pharmaceutical Ltd.)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24
Study: 21262278

Group type: EXPERIMENTAL
Intervention: Alcohol administration in a laboratory experiment
Number of subjects: 155

Group type: COMPARATOR
Intervention: Non-Alcohol Condition
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Blood Alcohol Level
Number of subjects: 155
Study: 19010571

Group type: EXPERIMENTAL
Intervention: High-polyunsaturated fatty acids from walnuts
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: High-monounsaturated fatty acids from olive oil
Number of subjects: 29

Group type: COMPARATOR
Intervention: High-saturated fatty acids from fat-rich dairy products
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Fat oxidation rates after unsaturated fatty acids meals
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Fat oxidation rates after high-saturated fatty acid meal
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Postprandial respiratory quotient, protein and carbohydrate oxidation, and satiety measures
Number of subjects: 29
Study: 17879021

Group type: EXPERIMENTAL
Intervention: Nicorandil (4 mg bolus injection followed by 8 mg/h infusion for 24 h)
Number of subjects: 62
Study: 15566926

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Estrogen-progestin replacement therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11565068

Group type: EXPERIMENTAL
Intervention: piperacillin‐tazobactam plus amikacin (7.5 mg/kg twice daily intravenously)
Number of subjects: 760

Group type: COMPARATOR
Intervention: piperacillin‐tazobactam plus placebo
Number of subjects: 760
Study: 9767221

Group type: EXPERIMENTAL
Intervention: Fetal pulse oximetry
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cardiotocography only
Number of subjects: 100
Study: 8152772

Group type: EXPERIMENTAL
Intervention: Topical 0.01% mitomycin C for 5 days
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Topical 0.02% mitomycin C for 5 days
Number of subjects: 75

Group type: COMPARATOR
Intervention: 1200 rad beta‐irradiation
Number of subjects: 75
Study: 3134560

Group type: EXPERIMENTAL
Intervention: 2-liter prepackaged enteral diet delivery system (2000 kcal, 12 g N)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1-liter rigid plastic containers filled with cans of Clinifeed 400
Number of subjects: 40
Study: 30221457

Group type: EXPERIMENTAL
Intervention: 75% of usual insulin degludec (IDeg) dose
Number of subjects: 9

Group type: COMPARATOR
Intervention: 100% of usual insulin degludec (IDeg) dose
Number of subjects: 9
Study: 28600398

Group type: EXPERIMENTAL
Intervention: plasma mF
Number of subjects: 924

Group type: EXPERIMENTAL
Intervention: plasma UFA
Number of subjects: 924
Study: 26403827

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) for harmful alcohol consumption (AUDIT ≥ 8)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 73
Study: 23963821

Group type: EXPERIMENTAL
Intervention: Surgical oophorectomy plus tamoxifen therapy
Number of subjects: 270
Study: 20498606

Group type: EXPERIMENTAL
Intervention: Local anaesthesia with dexmedetomidine (LAD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 60
Study: 19080698

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor and levofloxacin based triple therapy
Number of subjects: 1926
Study: 16193302

Group type: EXPERIMENTAL
Intervention: 8 kg tension
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 12 kg tension
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 15 kg tension
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (no specific tension mentioned)
Number of subjects: 48
Study: 12496537

Group type: EXPERIMENTAL
Intervention: GLY-GLN (0.5 g/kg/24 h)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: ALA-GLN (0.5 g/kg/24 h)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Vamin (GLN-free amino acid solution; control group)
Number of subjects: 45
Study: 11040017

Group type: EXPERIMENTAL
Intervention: Invasive treatment
Number of subjects: 113

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 113
Study: 8899661

Group type: EXPERIMENTAL
Intervention: Manual Muscle Testing (MMT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Maximal Voluntary Isometric Contraction (MVIC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ALS Score
Number of subjects: 20
Study: 1642145

Group type: EXPERIMENTAL
Intervention: Weight training
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Running
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control
Number of subjects: 31
Study: 6200411

Group type: EXPERIMENTAL
Intervention: Oxypertine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hydroxyzine pamoate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31843840

Group type: EXPERIMENTAL
Intervention: Multimodal occupational rehabilitation programme ('Beyond Cancer')
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care group (historical)
Number of subjects: 0
Study: 29122185

Group type: EXPERIMENTAL
Intervention: Smartphone width of 67 mm
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Smartphone width of 70 mm
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Smartphone width of 72 mm
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Smartphone width of 74 mm
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bottom bezel level of 2.5 mm
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bottom bezel level of 5 mm
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bottom bezel level of 7.5 mm
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bottom bezel level of 10 mm
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bottom bezel level of 12.5 mm
Number of subjects: 20
Study: 26611433

Group type: EXPERIMENTAL
Intervention: Group-based lifestyle intervention (GLI) offered by the YMCA, participation encouraged but not required.
Number of subjects: 331

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 331
Study: 25172519

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study: 22078129

Group type: EXPERIMENTAL
Intervention: Rizatriptan 10-mg ODT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20619137

Group type: EXPERIMENTAL
Intervention: Liangxue Jiedu Huoxue Decoction
Number of subjects: 100

Group type: COMPARATOR
Intervention: Radiotherapy alone (Control)
Number of subjects: 100
Study: 18005423

Group type: EXPERIMENTAL
Intervention: Education and Activation Programme (EAP) as an addition to usual care (UC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care (UC) only
Number of subjects: 0
Study: 16099694

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 12145055

Group type: EXPERIMENTAL
Intervention: Mivacurium 0.2 mg/kg injected over 10 s
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Mivacurium 0.2 mg/kg injected over 30 s
Number of subjects: 206
Study: 10204554

Group type: EXPERIMENTAL
Intervention: 24 hours of intravenous cefoxitin (1 g q6h)
Number of subjects: 314

Group type: COMPARATOR
Intervention: 5 days of intravenous cefoxitin
Number of subjects: 314
Study: 8706191

Group type: EXPERIMENTAL
Intervention: Ondansetron (OND) 150 micrograms x kg(‐1)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Droperidol (DROP) 50 micrograms x kg(‐1)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Ondansetron (OND)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Droperidol (DROP)
Number of subjects: 276
Study: 2079453

Group type: EXPERIMENTAL
Intervention: Tobramycin (three-day course)
Number of subjects: 1429

Group type: EXPERIMENTAL
Intervention: Gentamicin (two to three days)
Number of subjects: 1429

Group type: COMPARATOR
Intervention: Teicoplanin (non-toxic antibiotic)
Number of subjects: 1429
Study: 7418154

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg/day for 8 weeks
Number of subjects: 12
Study: 31992459

Group type: COMPARATOR
Intervention: Dapagliflozin alone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lobeglitazone alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Coadministration of lobeglitazone and dapagliflozin
Number of subjects: 40
Study: 31652512

Group type: EXPERIMENTAL
Intervention: Personalized energy-restricted diet
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Higher adherence to the Mediterranean Diet (MedDiet)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Energy-restricted diets
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Antioxidant capacity of the diet
Number of subjects: 98
Study: 29256406

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (250 mg/day of magnesium oxide)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 24676874

Group type: EXPERIMENTAL
Intervention: School readiness intervention focusing on children's self-regulation skills and parenting
Number of subjects: 0
Study: 23829828

Group type: EXPERIMENTAL
Intervention: rHuEPO (200 U/kg intravenously three days before operation and 100 U/kg at operation time)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 100
Study: 21454236

Group type: EXPERIMENTAL
Intervention: Insulin lispro with meals and basal insulin glargine
Number of subjects: 60
Study: 19358497

Group type: EXPERIMENTAL
Intervention: Meridian three-combined therapy (thread embedding, blood-letting puncture, auricular point pressing)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Di yin Tablets (5 tablets, twice daily)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Meridian three-combined therapy
Number of subjects: 233

Group type: COMPARATOR
Intervention: Di yin Tablets
Number of subjects: 233
Study: 16920998

Group type: EXPERIMENTAL
Intervention: Psychosocial interventions aimed at decreasing caregiver depression and burden
Number of subjects: 694

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 694
Study: 12952724

Group type: EXPERIMENTAL
Intervention: Telenursing service using an analogue videophone linked with a physiological monitoring device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing home care service (comparison arm)
Number of subjects: 0
Study: 10983644

Group type: EXPERIMENTAL
Intervention: Cidofovir 5 mg/kg once weekly for 2 weeks followed by low-dose maintenance cidofovir therapy (3 mg/kg)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Cidofovir 5 mg/kg once weekly for 2 weeks followed by high-dose maintenance cidofovir therapy (5 mg/kg)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Cidofovir
Number of subjects: 58
Study: 9098014

Group type: EXPERIMENTAL
Intervention: Ethanol (0.5 g/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Noncaloric fruit drink (250 mL)
Number of subjects: 16
Study: 7939946

Group type: COMPARATOR
Intervention: 300 mg polymorph A
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: 300 mg polymorph C
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: 500 mg polymorph C
Number of subjects: 958

Group type: COMPARATOR
Intervention: 100 mg polymorph C bid for 3 days (standard dose control)
Number of subjects: 958

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 958
Study: 2428795

Group type: EXPERIMENTAL
Intervention: Mantle field irradiation
Number of subjects: 318

Group type: COMPARATOR
Intervention: MOPP chemotherapy
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Extended field irradiation
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: ABVD chemotherapy
Number of subjects: 318
Study: 31207400

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (DES)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Paclitaxel-coated balloons (DCB)
Number of subjects: 88
Study: 29055674

Group type: EXPERIMENTAL
Intervention: Structured exercise programme (aerobic and resistance exercises) plus standard antenatal care
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard antenatal care
Number of subjects: 38
Study: 27855051

Group type: EXPERIMENTAL
Intervention: Carbetocin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 120
Study: 23980529

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) or Methotrexate + Cyclosporin A (MTX/CyA) treatment for 1 year
Number of subjects: 160

Group type: COMPARATOR
Intervention: Baseline characteristics (not an intervention)
Number of subjects: 160
Study: 22537359

Group type: EXPERIMENTAL
Intervention: Mecamylamine (0.5 mg/day for 6 weeks, 2.5 mg for 2 weeks, then 5 mg/day for 6 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mecamylamine (0.13-0.15 mg/kg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mecamylamine (≥0.18 mg/kg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mecamylamine
Number of subjects: 20
Study: 20097325

Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide implant placement
Number of subjects: 255

Group type: COMPARATOR
Intervention: Systemic corticosteroid therapy (and immunosuppression when indicated)
Number of subjects: 255
Study: 18088560

Group type: EXPERIMENTAL
Intervention: Dronabinol (10 mg or 20 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dronabinol (titrated in Phase II)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16893381

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Combination of tropisetron and dexamethasone
Number of subjects: 320
Study: 15221995

Group type: EXPERIMENTAL
Intervention: sTNFR‐I
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: sTNFR‐II
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: CA 125
Number of subjects: 139
Study: 11698939

Group type: EXPERIMENTAL
Intervention: Desmopressin (0.3 microg/kg at the end of cardiopulmonary bypass)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study: 9440364

Group type: EXPERIMENTAL
Intervention: Forward translation (L1 to L2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Backward translation (L2 to L1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Matching L1 item to a category name
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjustment procedure for response production and concept retrieval times
Number of subjects: 0
Study: 7513587

Group type: EXPERIMENTAL
Intervention: Verbal teaching and a color‐coded medication schedule
Number of subjects: 80

Group type: COMPARATOR
Intervention: Verbal teaching only
Number of subjects: 80
Study: 3118351

Group type: EXPERIMENTAL
Intervention: sulphinpyrazone
Number of subjects: 55

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 55
Study: 28993887

Group type: EXPERIMENTAL
Intervention: Everolimus 4.5 mg/m2/day (target blood trough 5-15 mg/dl)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 27049055

Group type: EXPERIMENTAL
Intervention: Test formulation of emtricitabine (EMT) 200 mg and tenofovir disoproxil fumarate (TNF) 300 mg
Number of subjects: 24